NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee A meeting minutes

**Minutes:** Confirmed

**Date:** Tuesday 5 September 2023

**Location:** 2 Redman Pl, London E20 1JQ and via Zoom

## Attendees

Committee members present

1. Dr Radha Todd (Chair) Present for all items
2. Dr James Fotheringham (Vice-chair) Present for all items
3. Alan Thomas Present for all items
4. Ana Duarte Present for all items
5. Andrew Champion Present for all items
6. Becky Pennington Present for all items
7. Dominic Pivonka Present for all items
8. Dr Craig Buckley Present for items 1.1 to 4.1.5
9. Dr Fiona MacPherson Smith Present for all items
10. Dr Justin Daniels Present for all items
11. Dr Mohit Sharma Present for items 1.1 to 4.1.5
12. Dr Peter Baker-Gulliver Present for items 1.1 to 4.1.5
13. Dr Steve Edwards Present for all items
14. Jaqueline Tomlinson Present for all items
15. Min Ven Teo Present for items 1.1 to 4.1.5
16. Mohamad Farhat Present for all items

NICE staff (key players) present

Jacoline Bouvy, Programme Director Present for all items

Janet Robertson, Associate Director Items 1.1 to 5.2.2

Thomas Feist, Project Manager Items 1.1 to 5.2.2

Marcia Miller, Administrator Items 1.1 to 5.2.2

Joanna Richardson, Heath Technology Assessment Adviser Items 1.1 to 4.1.5

Albany Chandler, Heath Technology Assessment Analyst Items 1.1 to 4.1.5

Claire Hawksworth, Heath Technology Assessment Adviser Items 5.1 to 5.2.2

Sharlene Ting, Heath Technology Assessment Analyst Items 5.1 to 5.2.2

Carl Jackson, Assistant Project Manager Present for all items

Portia Dodds, Coordinator Present for all items

External assessment group representatives present

Sarah Davis, School of Health and Related Research (ScHARR)  Items 1.1 to 5.1.3

Emma Hock, School of Health and Related Research (ScHARR) Items 1.1 to 4.1.3

Andrew Metry, Kleijnen Systematic Reviews Ltd Items 5.1 to 5.1.3

Clinical, Patient & NHS England experts present

Abby Macbeth, Consultant Dermatologist, Clinical expert Clinical expert nominated by BAD Items 1.1 to 4.1.3

Nekma Meah, Consultant Dermatologist , Clinical expert nominated by BAD Items 1.1 to 4.1.3

Lynn Wilks , Patient expert nominated by Alopecia UK Items 1.1 to 4.1.3

Tony Ferguson, Patient expert nominated by Alopecia UK Items 1.1 to 4.1.3

Peter Clark, CDF representative, NHS England Items 5.1 to 5.1.3

Peter Schmid, Centre Lead, Centre of Experimental Cancer Medicines, Clinical expert nominated by Daiichi-Sankyo Items 5.1 to 5.1.3

Holly Heath, Patient expert nominated by Breast Cancer Now

Items 5.1 to 5.1.3

Kirstin Spencer, Patient expert nominated by METUP Items 5.1 to 5.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair, Radha Todd, welcomed members of the committee and other attendees to the meeting.
  2. The chair noted apologies from Richard Ballerand, Hugo Pedder, Dr Patrick De Barr.

### News and announcements

* Dr Ravi Ramessur – new committee member

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 1 August 2023.

### Appraisal of [Ritlecitinib for treating severe alopecia areata in people 12 years and over [ID4007]](https://www.nice.org.uk/guidance/indevelopment/gid-ta11037)

* 1. Part 1 – Private session
     1. The Chair, James Fotheringham, welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Pfizer.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10813).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Mohamed Farhat (clinical), Alan Thomas (lay), Dominic Pivonka (cost).

Part 2 - Closed session (company representatives, clinical and patient experts and external assessment group representatives were asked to leave the meeting)

* + 1. The committee then agreed on the content of the Draft Guidance (DG). The committee decision was reached by consensus.
    2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10813>

### Appraisal of [trastuzumab deruxtecan for treating HER2-Low metastatic or unresectable breast cancer after chemotherapy ID3935](https://www.nice.org.uk/guidance/indevelopment/gid-ta10813)

* 1. Part 1 – Open session
     1. The Chair, Radha Todd, welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Daiichi Sankyo.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here.](https://www.nice.org.uk/guidance/indevelopment/gid-ta10813)
     3. The Chair, Radha Todd, led a discussion of the consultation comments presented to the committee. This information was presented to the committee by NAMES.
  2. Part 2 - Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare Final Draft Guidance in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10813>

### Appraisal of [talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations [ID1342]](https://www.nice.org.uk/guidance/indevelopment/gid-ta10366)

This topic was postponed until the next committee meeting.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee A will be held on Tuesday 3 October 2023 and will start promptly at 9:00.